




# BIOTECHNOLOGY




## MARKET SIZE

India Biotechnology industry valuation (US\$ billion)



## APPROVALS

Number of biologics and biosimilars approved in India




Note: \* As of April 2025





## KEY TRENDS

Clinical trials market in India (US\$ billion)



Medical device market in India (US\$ billion)



## GOVERNMENT INITIATIVES



Make in India



Biotech Parks



National Biopharma Mission



## ADVANTAGE INDIA

- Skilled human capital:** With a total population of 1.4 billion, 47% being under the age of 25, India has a large pool of young and skilled workforce. India has a large reservoir of scientific human resources, including scientists and engineers.
- Government Support:** The Union Budget 2025-26 strengthens India's biotechnology sector with increased funding for the Department of Biotechnology (DBT) to support R&D, biomanufacturing, and startups. It allocates Rs. 20,000 crore (US\$ 2.30 billion) for private research, launches the National Manufacturing Mission, and promotes AI-driven biotech, precision farming, biofuels, and genetic research, driving innovation and sustainability. The government envisions creating biofoundries, Bio AI centres, and thematic hubs focused on bio-based chemicals, smart proteins, and carbon capture as part of policy support to foster biomanufacturing and innovation.
- FDI Policy:** 100% under automatic route for greenfield projects for pharmaceuticals; 100% under automatic route is allowed for the manufacturing of medical devices.
- Epidemiological factors:** The patient pool is expected to increase over 20% in the next 10 years, mainly due to a rise in population.